Filing Details
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) filed a Form 8-K with the Securities and Exchange Commission on October 16, 2026, disclosing a material event.
8k filedNASDAQ:PMCB
PharmaCyte Biotech, Inc. (PMCB) Reports Material Event to SEC
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) filed a Form 8-K with the Securities and Exchange Commission on October 16, 2026, disclosing a material event.
At publication ·
What changed
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- PharmaCyte Biotech filed a Form 8-K on October 16, 2026, disclosing a material event to shareholders.
- The company's stock trades at $0.34 with a market capitalization of $6.9 million.
- Form 8-K filings report material events such as leadership changes, acquisitions, asset sales, or financial guidance updates.
Market Context
PharmaCyte Biotech, Inc.'s stock currently trades at $0.34 with a market capitalization of $6.9M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for PharmaCyte Biotech, Inc.'s stock.
All SEC filings for PharmaCyte Biotech, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PMCB Stock Page
Frequently Asked Questions
Where can I read PMCB's SEC filings?
Browse all filings on our PMCB SEC filings page.
What types of SEC filings does PharmaCyte Biotech, Inc. file?
Public companies like PharmaCyte Biotech, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.